I
DaTSCAN
Parkinsonism
SPECT
nigrostriatal pathway
Journal
Movement disorders clinical practice
ISSN: 2330-1619
Titre abrégé: Mov Disord Clin Pract
Pays: United States
ID NLM: 101630279
Informations de publication
Date de publication:
01 May 2024
01 May 2024
Historique:
revised:
23
01
2024
received:
14
11
2023
accepted:
30
03
2024
medline:
2
5
2024
pubmed:
2
5
2024
entrez:
2
5
2024
Statut:
aheadofprint
Résumé
As the diagnosis of Parkinson's disease (PD) is fundamentally clinical, the usefulness of ioflupane ( We aimed to summarize the current literature regarding DaTSCAN findings in patients with rare neurodegenerative parkinsonisms. The PubMed database was systematically screened for studies in English or Spanish up to October 15, 2023, using search terms "DaTSCAN", "ioflupane", "DaT-SPECT", "123I-FP-CIT SPECT", "dopamine transporter imaging", and "[123I] FP-CIT SPECT". Duplicated publications and studies regarding PD, atypical parkinsonisms, dystonia-parkinsonism, essential tremor, and parkinsonism due to non-degenerative causes were excluded. The obtained results were reviewed and summarized, including DaTSCAN findings in fragile X-associated tremor/ataxia syndrome, prion diseases, Huntington's disease, spinocerebellar ataxia, hereditary spastic paraparesis, metabolic disorders, and other diseases (anti-IgLON5 disease, ring chromosome 20 syndrome, chorea-acanthocytosis, and neuronal ceroid lipofuscinosis). This review highlights the need to determine in the future the utility and cost-effectiveness of DaTSCAN, both as a diagnostic and a prognostic tool, in patients with parkinsonian symptoms in rare neurodegenerative diseases.
Sections du résumé
BACKGROUND
BACKGROUND
As the diagnosis of Parkinson's disease (PD) is fundamentally clinical, the usefulness of ioflupane (
OBJECTIVES
OBJECTIVE
We aimed to summarize the current literature regarding DaTSCAN findings in patients with rare neurodegenerative parkinsonisms.
METHODS
METHODS
The PubMed database was systematically screened for studies in English or Spanish up to October 15, 2023, using search terms "DaTSCAN", "ioflupane", "DaT-SPECT", "123I-FP-CIT SPECT", "dopamine transporter imaging", and "[123I] FP-CIT SPECT". Duplicated publications and studies regarding PD, atypical parkinsonisms, dystonia-parkinsonism, essential tremor, and parkinsonism due to non-degenerative causes were excluded.
RESULTS
RESULTS
The obtained results were reviewed and summarized, including DaTSCAN findings in fragile X-associated tremor/ataxia syndrome, prion diseases, Huntington's disease, spinocerebellar ataxia, hereditary spastic paraparesis, metabolic disorders, and other diseases (anti-IgLON5 disease, ring chromosome 20 syndrome, chorea-acanthocytosis, and neuronal ceroid lipofuscinosis).
CONCLUSIONS
CONCLUSIONS
This review highlights the need to determine in the future the utility and cost-effectiveness of DaTSCAN, both as a diagnostic and a prognostic tool, in patients with parkinsonian symptoms in rare neurodegenerative diseases.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 International Parkinson and Movement Disorder Society.
Références
Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol 2006;5(1):75–86. https://doi.org/10.1016/S1474-4422(05)70285-4.
Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015;30(12):1591–1601. https://doi.org/10.1002/mds.26424.
Verger A, Grimaldi S, Ribeiro M, Frismand S, Guedj E. Single photon emission computed tomography/positron emission tomography molecular imaging for parkinsonism: a fast‐developing field. Ann Neurol 2021;90(5):711–719. https://doi.org/10.1002/ana.26187.
Berardelli A, Wenning GK, Antonini A, et al. EFNS/MDS‐ES recommendations for the diagnosis of Parkinson's disease. Eur J Neurol 2013;20(1):16–34. https://doi.org/10.1111/ene.12022.
Marshall VL, Reininger CB, Marquardt M, et al. Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3‐year European multicenter study with repeat [ 123 I]FP‐CIT SPECT. Mov Disord 2009;24(4):500–508. https://doi.org/10.1002/mds.22108.
Darcourt J, Booij J, Tatsch K, et al. EANM procedure guidelines for brain neurotransmission SPECT using 123I‐labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging 2010;37(2):443–450. https://doi.org/10.1007/s00259-009-1267-x.
Chahid Y, Sheikh ZH, Mitropoulos M, Booij J. A systematic review of the potential effects of medications and drugs of abuse on dopamine transporter imaging using [123I]I‐FP‐CIT SPECT in routine practice. Eur J Nucl Med Mol Imaging 2023;50(7):1974–1987. https://doi.org/10.1007/s00259-023-06171-x.
Marek K, Seibyl J, Eberly S, et al. Longitudinal follow‐up of SWEDD subjects in the PRECEPT study. Neurology 2014;82(20):1791–1797. https://doi.org/10.1212/WNL.0000000000000424.
de la Fuente‐Fernandez R. Role of DaTSCAN and clinical diagnosis in Parkinson disease. Neurology 2012;78(10):696–701. https://doi.org/10.1212/WNL.0b013e318248e520.
Morbelli S, Esposito G, Arbizu J, et al. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in parkinsonian syndromes 1.0. Eur J Nucl Med Mol Imaging 2020;47(8):1885–1912. https://doi.org/10.1007/s00259-020-04817-8.
Kagi G, Bhatia KP, Tolosa E. The role of DAT‐SPECT in movement disorders. J Neurol Neurosurg Psychiatry 2010;81(1):5–12. https://doi.org/10.1136/jnnp.2008.157370.
Perlmutter JS, Eidelberg D. To scan or not to scan: DaT is the question. Neurology 2012;78(10):688–689. https://doi.org/10.1212/WNL.0b013e3182494c72.
Badoud S, Van De Ville D, Nicastro N, Garibotto V, Burkhard PR, Haller S. Discriminating among degenerative parkinsonisms using advanced 123 I‐ioflupane SPECT analyses. Neuroimage Clin 2016;12:234–240. https://doi.org/10.1016/j.nicl.2016.07.004.
Bega D, Kuo PH, Chalkidou A, et al. Clinical utility of DaTscan in patients with suspected parkinsonian syndrome: a systematic review and meta‐analysis. NPJ Parkinsons Dis 2021;7(1):43. https://doi.org/10.1038/s41531-021-00185-8.
Mehanna R, Jimenez‐Shahed J, Itin I. Three cases of levodopa‐resistant parkinsonism after radiation therapy. Am J Case Rep 2016;17:916–920. https://doi.org/10.12659/AJCR.900537.
Erro R, Pappata S, Picillo M, et al. Teaching NeuroImages: pseudo‐abnormal DaTscan findings in meningioma‐induced parkinsonism. Neurology 2013;80(13):e147. https://doi.org/10.1212/WNL.0b013e318289709d.
Méndez‐Guerrero A, Laespada‐García MI, Gómez‐Grande A, et al. Acute hypokinetic‐rigid syndrome following SARS‐CoV‐2 infection. Neurology 2020;95(15):e2109–e2118. https://doi.org/10.1212/WNL.0000000000010282.
Ceravolo R, Antonini A, Volterrani D, et al. Dopamine transporter imaging study in parkinsonism occurring in fragile X premutation carriers. Neurology 2005;65(12):1971–1973. https://doi.org/10.1212/01.wnl.0000188821.51055.52.
Hall DA, Jennings D, Seibyl J, Tassone F, Marek K. FMR1 gene expansion and scans without evidence of dopaminergic deficits in parkinsonism patients. Parkinsonism Relat Disord 2010;16(9):608–611. https://doi.org/10.1016/j.parkreldis.2010.07.006.
Healy DG, Bressman S, Dickson J, et al. Evidence for pre and postsynaptic nigrostriatal dysfunction in the fragile X tremor‐ataxia syndrome. Mov Disord 2009;24(8):1245–1247. https://doi.org/10.1002/mds.22267.
Scaglione C, Ginestroni A, Vella A, et al. MRI and SPECT of midbrain and striatal degeneration in fragile X‐associated tremor/ataxia syndrome. J Neurol 2008;255(1):144–146. https://doi.org/10.1007/s00415-007-0711-8.
Madeo G, Alemseged F, di Pietro B, Schillaci O, Pisani A. Early abnormalities in 123I‐ioflupane (DaTSCAN) imaging in the fragile X‐associated tremor ataxia syndrome (FXTAS): a case report. Neurol Sci 2013;34(8):1475–1477. https://doi.org/10.1007/s10072-012-1223-6.
Apartis E, Blancher A, Meissner WG, et al. FXTAS: new insights and the need for revised diagnostic criteria. Neurology 2012;79(18):1898–1907. https://doi.org/10.1212/WNL.0b013e318271f7ff.
Hinnell C, Buxton‐Thomas M, Sibtain N, Samuel M. Striatal 123I‐Ioflupane SPECT abnormality in sporadic Creutzfeldt–Jakob disease. J Neurol 2011;258(5):948–950. https://doi.org/10.1007/s00415-010-5860-5.
Tomizawa Y, Taniguchi D, Furukawa Y. Genetic Creutzfeldt‐Jakob disease mimicking dementia with Lewy bodies: clinical and radiological findings. J Neurol Sci 2020;409:116604. https://doi.org/10.1016/j.jns.2019.116604.
Renard D, Collombier L, Ayrignac X, Bouttier F, Kotzki PO, Labauge P. [123I] FP‐CIT SPECT in Creutzfeldt–Jakob disease. J Neurol 2010;257(10):1754–1755. https://doi.org/10.1007/s00415-010-5594-4.
Fukuoka T, Nakazato Y, Yamamoto M, Miyake A, Mitsufuji T, Yamamoto T. Fatal familial insomnia initially developing parkinsonism mimicking dementia with Lewy bodies. Intern Med 2018;57(18):2719–2722. https://doi.org/10.2169/internalmedicine.0573-17.
García C, de León S, Cabello JP, Ortiz R, Vaamonde J. Parkinsonism associated with pathological 123I‐FP‐CIT SPECT (DaTSCAN) results as the initial manifestation of sporadic Creutzfeldt‐Jakob disease. Case Rep Neurol Med 2018;2018:1–3. https://doi.org/10.1155/2018/5157275.
Vital A, Fernagut PO, Canron MH, et al. The Nigrostriatal pathway in Creutzfeldt‐Jakob disease. J Neuropathol Exp Neurol 2009;68(7):809–815. https://doi.org/10.1097/NEN.0b013e3181abdae8.
Mulroy E, Latorre A, Menozzi E, Teh PC, Magrinelli F, Bhatia KP. Huntington disease like 2 (HDL‐2) with parkinsonism and abnormal DAT‐SPECT – a novel observation. Parkinsonism Relat Disord 2020;71:46–48. https://doi.org/10.1016/j.parkreldis.2020.01.008.
Gamez J, Lorenzo‐Bosquet C, Cuberas‐Borrós G, Carmona F, Hernández‐Vara J, Castilló J, Castell‐Conesa J. Does reduced [123I]‐FP‐CIT binding in Huntington's disease suggest pre‐synaptic dopaminergic involvement? Clin Neurol Neurosurg 2010;112(10):870–875. https://doi.org/10.1016/j.clineuro.2010.07.014.
Gamez J, Lorenzo‐Bosquet C, Cuberas‐Borrós G, et al. Progressive presynaptic dopaminergic deterioration in Huntington disease. Clin Nucl Med 2014;39(3):e227–e228. https://doi.org/10.1097/RLU.0b013e31828162cd.
Holmes SE, O'Hearn E, Rosenblatt A, et al. A repeat expansion in the gene encoding junctophilin‐3 is associated with Huntington disease–like 2. Nat Genet 2001;29(4):377–378. https://doi.org/10.1038/ng760.
Anderson DG, Walker RH, Connor M, Carr J, Margolis RL, Krause A. A systematic review of the Huntington disease‐like 2 phenotype. J Huntingtons Dis 2017;6(1):37–46. https://doi.org/10.3233/JHD-160232.
Tang C, Feigin A. Monitoring Huntington's disease progression through preclinical and early stages. Neurodegener Dis Manag 2012;2(4):421–435. https://doi.org/10.2217/nmt.12.34.
Pagano G, Niccolini F, Politis M. Current status of PET imaging in Huntington's disease. Eur J Nucl Med Mol Imaging 2016;43(6):1171–1182. https://doi.org/10.1007/s00259-016-3324-6.
Russell DS, Jennings DL, Barret O, et al. Change in PDE10 across early Huntington disease assessed by [ 18 F]MNI‐659 and PET imaging. Neurology 2016;86(8):748–754. https://doi.org/10.1212/WNL.0000000000002391.
Pulido‐Valdeolivas I, Gómez‐Andrés D, Sanz‐Gallego I, Rausell E, Arpa J. Patterns of motor signs in spinocerebellar ataxia type 3 at the start of follow‐up in a reference unit. Cerebellum Ataxias 2016;3(1):4. https://doi.org/10.1186/s40673-016-0042-6.
Bonnet C, Apartis E, Anheim M, et al. Tremor‐spectrum in spinocerebellar ataxia type 3. J Neurol 2012;259(11):2460–2470. https://doi.org/10.1007/s00415-012-6531-5.
Miyaue N, Tada S, Ando R, et al. DAT SPECT may have diagnostic value in prodromal SCA2 patients with parkinsonism. Parkinsonism Relat Disord 2017;44:137–141. https://doi.org/10.1016/j.parkreldis.2017.08.012.
Xie T, Appelbaum D, Bernard J, Padmanaban M, Pu Y, Gomez C. Evaluation of parkinsonism and striatal dopamine transporter loss in patients with spinocerebellar ataxia type 6. J Neurol 2016;263(11):2302–2307. https://doi.org/10.1007/s00415-016-8261-6.
Latorre A, del Gamba C, Menozzi E, Balint B, Brugger F, Bhatia KP. Abnormal DaTSCAN and atypical parkinsonism in SCA12. Mov Disord Clin Pract. 2019;6(5):400–402. https://doi.org/10.1002/mdc3.12751.
Onder H, Comoglu S. A rare patient with hereditary spastic Paraparesis with parkinsonism. Asian J Neurosurg 2023;18(1):216–218. https://doi.org/10.1055/s-0043-1764117.
Bellini G, del Prete E, Unti E, Frosini D, Siciliano G, Ceravolo R. Positive DAT‐SCAN in SPG7: a case report mimicking possible MSA‐C. BMC Neurol 2021;21(1):328. https://doi.org/10.1186/s12883-021-02345-y.
Anheim M, Lagier‐Tourenne C, Stevanin G, et al. SPG11 spastic paraplegia. J Neurol 2009;256(1):104–108. https://doi.org/10.1007/s00415-009-0083-3.
Salgado P, Latorre A, del Gamba C, Menozzi E, Balint B, Bhatia KP. SPG7: the great imitator of MSA‐C within the ILOCAs. Mov Disord Clin Pract. 2019;6(2):174–175. https://doi.org/10.1002/mdc3.12711.
Paghera B, Caobelli F, Giubbini R. 123 I‐Ioflupane SPECT in Fahr disease. J Neuroimaging 2013;23(1):157–158. https://doi.org/10.1111/j.1552-6569.2011.00581.x.
Kalampokini S, Georgouli D, Dadouli K, et al. Fahr's syndrome due to hypoparathyroidism revisited: a case of parkinsonism and a review of all published cases. Clin Neurol Neurosurg 2021;202:106514. https://doi.org/10.1016/j.clineuro.2021.106514.
Caranci G, Grillea G, Barbato F, et al. Scintigraphic, neuroradiological and clinical comparison in two patients with primary sporadic and two with secondary Fahr's disease. Neurol Sci 2011;32(2):337–341. https://doi.org/10.1007/s10072-010-0444-9.
Frantellizzi V, Pontico M, Pani A, de Feo MS, de Vincentis G. 123I‐FP‐CIT brain SPECT findings in succinic Semialdehyde dehydrogenase (SSADH) deficiency. Curr Radiopharm 2021;14(1):78–83. https://doi.org/10.2174/1874471013666200325101302.
Marangi A, Tagliapietra M, Vicenzi V, Pasquin I, Salviati A. Teaching NeuroImages: brain MRI and DaT‐SPECT imaging in adult GM1 gangliosidosis. Neurology 2018;91(2):e187–e188. https://doi.org/10.1212/WNL.0000000000005775.
Koya Kutty S, Magrinelli F, Milner AV, Bhatia KP. Abnormal <scp>DaTscan</scp> in <scp>GM1</scp> ‐Gangliosidosis type <scp>III</scp> manifesting with dystonia‐parkinsonism. Mov Disord Clin Pract 2022;9(6):825–828. https://doi.org/10.1002/mdc3.13512.
Kang A, Minoshima S. 123I‐Ioflupane SPECT findings of Pantothenate kinase–associated neurodegeneration. Clin Nucl Med 2014;39(9):849–851. https://doi.org/10.1097/RLU.0000000000000409.
Santoro L, Breedveld GJ, Manganelli F, et al. Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability. Neurogenetics 2011;12(1):33–39. https://doi.org/10.1007/s10048-010-0259-0.
Benger M, Mankad K, Proukakis C, Mazarakis ND, Kinali M. The interaction of genetic mutations in PARK2 and FA2H causes a novel phenotype in a case of childhood‐onset movement disorder. Front Neurol 2019;10:555. https://doi.org/10.3389/fneur.2019.00555.
Dusi S, Valletta L, Haack TB, et al. Exome sequence reveals mutations in CoA synthase as a cause of neurodegeneration with brain iron accumulation. Am J Hum Genet 2014;94(1):11–22. https://doi.org/10.1016/j.ajhg.2013.11.008.
González‐Ávila C, Casado L, Muro García I, Villacieros‐Álvarez J, Vivancos J, Quintas S. Altered ioflupane single‐photon emission computed tomography in anti‐IgLON5 disease: a new case mimicking probable progressive supranuclear palsy and review of the literature. Eur J Neurol 2021;28(4):1392–1395. https://doi.org/10.1111/ene.14634.
Brüggemann N, Wandinger KP, Gaig C, Sprenger A, Junghanns K, Helmchen C, Münchau A. Dystonia, lower limb stiffness, and upward gaze palsy in a patient with IgLON5 antibodies. Mov Disord 2016;31(5):762–764. https://doi.org/10.1002/mds.26608.
Fuseya K, Kimura A, Yoshikura N, Yamada M, Hayashi Y, Shimohata T. Corticobasal syndrome in a patient with <scp>anti‐IgLON5</scp> antibodies. Mov Disord Clin Pract 2020;7(5):557–559. https://doi.org/10.1002/mdc3.12957.
Montojo T, Piren V, Benkhadra F, Codreanu A, Diederich NJ. Gaze palsy, sleep and gait disorder, as well as Tako‐Tsubo syndrome in a patient with IgLON5 antibodies. Mov Disord Clin Pract 2017;4(3):441–443. https://doi.org/10.1002/mdc3.12407.
del Sole A, Chiesa V, Lucignani G, et al. Exploring dopaminergic activity in ring chromosome 20 syndrome: a SPECT study. Quart J Nucl Med Mol Imaging 2010;54(5):564–569.
Niemelä V, Salih A, Solea D, et al. Phenotypic variability in chorea‐acanthocytosis associated with novel VPS13A mutations. Neurol Genet 2020;6(3):e426. https://doi.org/10.1212/NXG.0000000000000426.
Schulz A, Kohlschütter A, Mink J, Simonati A, Williams R. NCL diseases — clinical perspectives. Biochim Biophys Acta (BBA) – Mol Basis Dis 2013;1832(11):1801–1806. https://doi.org/10.1016/j.bbadis.2013.04.008.
Jalanko A, Braulke T. Neuronal ceroid lipofuscinoses. Biochim Biophys Acta (BBA) – Mol Cell Res 2009;1793(4):697–709. https://doi.org/10.1016/j.bbamcr.2008.11.004.
Lange LM, Schell N, Tunc S, Shoukier M, Weißbach A, Hellenbroich Y, Brüggemann N. Atypical parkinsonism with pathological dopamine transporter imaging in neuronal ceroid Lipofuscinosis type 5. Mov Disord Clin Pract 2022;9(8):1116–1119. https://doi.org/10.1002/mdc3.13562.
Bajaj N, Hauser RA, Grachev ID. Clinical utility of dopamine transporter single photon emission CT (DaT‐SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. J Neurol Neurosurg Psychiatry 2013;84(11):1288–1295. https://doi.org/10.1136/jnnp-2012-304436.
Gajos A, Dąbrowski J, Bieńkiewicz M, Płachcińska A, Kuśmierek J, Bogucki A. Should non‐movement specialists refer patients for SPECT‐DaTSCAN? Neurol Neurochir Pol 2019;53(2):138–143. https://doi.org/10.5603/PJNNS.a2019.0011.
Graebner AK, Tarsy D, Shih LC, et al. Clinical Impact of 123I‐Ioflupane SPECT (DaTscan) in a Movement Disorder Center. Neurodegener Dis 2017;17(1):38–43. https://doi.org/10.1159/000447561.
Isaacson JR, Brillman S, Chhabria N, Isaacson SH. Impact of DaTscan imaging on clinical decision making in clinically uncertain Parkinson's disease. J Parkinsons Dis 2021;11(2):885–889. https://doi.org/10.3233/JPD-202506.